AAAAAA
Results:
1-12
|
Results: 12
Authors:
DIMMITT DC
HUNT TL
SPALITTO AJ
CRAMER MB
SHAH AK
ARUMUGHAM T
HAHNE W
Citation: Dc. Dimmitt et al., EFFECT OF INFUSION RATE ON THE PHARMACOKINETICS AND TOLERANCE OF INTRAVENOUS DOLASETRON MESYLATE, The Annals of pharmacotherapy, 32(1), 1998, pp. 39-44
Authors:
LIPPERT C
KEUNG A
ARUMUGHAM T
ELLER M
HAHNE W
WEIR S
Citation: C. Lippert et al., THE EFFECT OF FOOD ON THE BIOAVAILABILITY OF DOLASETRON MESYLATE TABLETS, Biopharmaceutics & drug disposition, 19(1), 1998, pp. 17-19
Authors:
KORTTILA K
CLERGUE F
LEESER J
FEISS P
OLTHOFF D
PAYEURMICHEL C
WESSEL P
NAVE S
HAHNE W
BROWN R
Citation: K. Korttila et al., INTRAVENOUS DOLASETRON AND ONDANSETRON IN PREVENTION OF POSTOPERATIVENAUSEA AND VOMITING - A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLEDSTUDY, Acta anaesthesiologica Scandinavica, 41(7), 1997, pp. 914-922
Authors:
BEY P
WILKINSON PM
RESBEUT M
BOURDIN S
LEFLOCH O
HAHNE W
CLAVERIE N
Citation: P. Bey et al., A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF IV DOLASETRON MESILATE INTHE PREVENTION OF RADIOTHERAPY-INDUCED NAUSEA AND VOMITING IN CANCER-PATIENTS, Supportive care in cancer, 4(5), 1996, pp. 378-383
Authors:
HESKETH P
NAVARI R
GROTE T
GRALLA R
HAINSWORTH J
KRIS M
ANTHONY L
KHOJASTEH A
TAPAZOGLOU E
BENEDICT C
HAHNE W
Citation: P. Hesketh et al., DOUBLE-BLIND, RANDOMIZED COMPARISON OF THE ANTIEMETIC EFFICACY OF INTRAVENOUS DOLASETRON MESYLATE AND INTRAVENOUS ONDANSETRON IN THE PREVENTION OF ACUTE CISPLATIN-INDUCED EMESIS IN PATIENTS WITH CANCER, Journal of clinical oncology, 14(8), 1996, pp. 2242-2249
Authors:
BENEDICT CR
ARBOGAST R
MARTIN L
PATTON L
MORRILL B
HAHNE W
Citation: Cr. Benedict et al., SINGLE-BLIND STUDY OF THE EFFECTS OF INTRAVENOUS DOLASETRON MESYLATE VERSUS ONDANSETRON ON ELECTROCARDIOGRAPHIC PARAMETERS IN NORMAL VOLUNTEERS, Journal of cardiovascular pharmacology, 28(1), 1996, pp. 53-59
Authors:
DIEMUNSCH P
LEESER J
HELMERS JH
WILKEY B
RADKE J
NAVE S
MCKENZIE K
HAHNE W
BROWN R
Citation: P. Diemunsch et al., ORAL DOLASETRON MESYLATE FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING (PONV), Anesthesiology, 85(3A), 1996, pp. 3-3
Authors:
WATKINS WD
KOVAC A
HICKOK C
MELSON T
DUBOIS D
HAHNE W
BROWN R
Citation: Wd. Watkins et al., EVALUATION OF OPTIMALLY EFFECTIVE IV DOSE OF DOLASETRON MESYLATE (DM)FOR TREATING ESTABLISHED POST OPERATIVE NAUSEA AND VOMITING (PONV), Anesthesiology, 85(3A), 1996, pp. 17-17
Authors:
KORTTILA K
MAILLET M
DIEMUNSCH P
BRULEMERY M
NAVE S
WILCKE S
HAHNE W
BROWN R
Citation: K. Korttila et al., IV DOLASETRON MESYLATE (DM) VS IV ONDANSETRON (OND) FOR PREVENTION OFPOST OPERATIVE NAUSEA AND VOMITING (PONV), Anesthesiology, 85(3A), 1996, pp. 35-35
Authors:
GROTE T
MODIANO M
GANDARA D
COCQUYT V
HAHNE W
Citation: T. Grote et al., 4 ARM ORAL DOSE-RESPONSE TRIAL OF DOLASETRON MESYLATE (DM) FOR PREVENTION OF EMESIS INDUCED BY PLATINUM-CONTAINING MODERATELY EMETOGENIC CHEMOTHERAPY (CT), European journal of cancer, 31A, 1995, pp. 1219-1219
Authors:
RUBENSTEIN E
COCQUYT V
MODIANO M
HESKETH P
HAHNE W
ANDERSON MD
Citation: E. Rubenstein et al., DOSE-RESPONSE TRIAL ACROSS 4 ORAL DOSES OF DOLASETRON (DM) FOR EMESISPREVENTION AFTER MODERATELY EMETOGENIC CHEMOTHERAPY (CT), European journal of cancer, 31A, 1995, pp. 1227-1227
Authors:
SHAH A
LANMAN R
BHARGAVA V
WEIR S
HAHNE W
Citation: A. Shah et al., PHARMACOKINETICS OF DOLASETRON FOLLOWING SINGLE-DOSE AND MULTIPLE-DOSE INTRAVENOUS ADMINISTRATION TO NORMAL-MALE SUBJECTS, Biopharmaceutics & drug disposition, 16(3), 1995, pp. 177-189
Risultati:
1-12
|